NCT02076633View on ClinicalTrials.gov

Intratumoral Administration of L19IL2/L19TNF

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Malignant Melanoma, Skin
Interventions
DRUG

L19IL2+L19TNF

Patients will be treated with intratumoral injections of 10 MioIU L19IL2 and 312μg L19TNF once weekly for up to 4 weeks.

Trial Locations (2)

Unknown

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

Azienda Ospedaliera Universitaria Senese, Siena

All Listed Sponsors
lead

Philogen S.p.A.

INDUSTRY

NCT02076633 - Intratumoral Administration of L19IL2/L19TNF | Biotech Hunter | Biotech Hunter